Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events - Wikidata - awgldk - TriplyDB

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

http://www.wikidata.org/entity/Q24629580

about

Lipoprotein(a) as a cardiovascular risk factor: current status Lipoprotein (a): structure, pathophysiology and clinical implications.Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy.Enigmatic role of lipoprotein(a) in cardiovascular disease.Update on the NCEP ATP-III emerging cardiometabolic risk factors.Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women.Lipoprotein(a): Cellular Effects and Molecular Mechanisms Lipoprotein(a) and cardiovascular disease in diabetic patients Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.Lipoprotein(a) and apolipoprotein(a) in polycystic ovary syndrome.Lipoprotein (a): impact by ethnicity and environmental and medical conditions Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.Estrogen-eluting stents.Lipoprotein(a) as a therapeutic target in cardiovascular disease.Ongoing challenges for pharmacotherapy for dyslipidemia.Targeting lipoprotein (a): an evolving therapeutic landscape.Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options.Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults

P2860

Q24623225-13D2967D-7D9C-41F6-A92E-9E8AB4F56ACB Q34020677-DDFF6155-AEF4-4AC4-AD76-0EAE013F7CD5 Q34116379-EE8F40FB-D9BB-4601-A0AD-A1C96CC5A173 Q34786504-C31DD2F9-DC5C-45D2-957F-F3551D93BCF7 Q34811590-7638A66B-603C-45EE-8358-1F724CC623D9 Q35093777-7D02C379-54EF-4439-8E11-6A23B660261F Q36237559-71501A7A-5064-4464-97AE-D445B1B7A75A Q36369444-91EBD0CA-40FD-4290-845B-A1AB4F69BCAF Q36515765-E686FB2B-490B-48CB-85A0-E23D41D331A4 Q36653816-90CAD281-BA19-4952-89B6-C5DF3523E952 Q37033161-8E8A85B4-9E0A-4778-A951-EEEB797208D2 Q37285933-4D47DB2C-8785-4355-92E2-E635A6820F0D Q37286107-B16C4C69-0949-46DC-85E8-99CF307ABE58 Q38213476-62389F61-56AF-49D7-A3A8-32C22D0CDF58 Q38283386-D7045594-13F0-4569-B985-A9BBD35CD618 Q38367355-2F3CEF1F-A534-4936-9ED2-402C7BEB6487 Q39054740-EF7B947A-CD62-4BAB-9EDD-EDB0C367B927 Q40601888-76ED510F-B07B-4425-85BB-A731221BA63E

P2860

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

http://www.wikidata.org/entity/Q24629580

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@ast

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@en

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@nl

type

label

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@ast

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@en

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@nl

prefLabel

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@ast

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@en

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@nl

P1433

Q24629580-EB8713E2-0318-422D-B695-1D4251AC4EF9

P1476

Q24629580-AE8B62C9-4BB4-4E1F-B4E5-2D2055A93673

P2093

Q24629580-061625DC-A3BA-46C8-84A4-F20DBBC703F6

Q24629580-771DC37D-32E4-4EF3-9485-74A78D73B4A5

P2860

Q24629580-1398FBA5-02BC-479A-A612-B560AA6CAF02

Q24629580-1C86E29E-35E7-4DDC-A684-D226D3721C96

Q24629580-1F36AA70-5F3A-442E-8077-8D2F7A16388B

Q24629580-24BEB8DA-6CFC-42B5-A538-3AEA5BD1166F

Q24629580-24C3E38B-7E06-491D-824C-313F730788F0

Q24629580-290626EB-D4ED-4280-B2A8-6BFC0C208C7C

Q24629580-2A463290-B7D2-41D0-9E27-2523324AFDD3

Q24629580-2D21E932-7B07-4A19-95D7-2ED51B42707A

Q24629580-33A87BBC-A0DB-41B8-92F3-03883684031E

Q24629580-34770B64-4439-41EF-B208-7440959260DA

P304

Q24629580-B9851245-2813-4F11-909F-42CDDED82472

P31

Q24629580-E00A2745-42AF-47B6-A581-4A95922F38E5

P356

Q24629580-7C399F6E-F784-4D73-A6C2-0C7889ECF9A2

P407

Q24629580-A4806394-55EB-41FD-BC90-DDFC3A2B462A

P433

Q24629580-2BA66847-3388-4873-9D66-AC26D2638814

P478

Q24629580-78291FEE-6C50-49CE-8B1E-6CA07CB7BE7B

P50

Q24629580-792B9664-6A6A-4B6F-BE0D-DC46B0FCD6DC

Q24629580-D4CCAA9C-D8DE-43FB-A2BA-ED55E8F9DDBC

P577

Q24629580-AE68CCD1-2C31-4966-BDC5-D001EEC28DBE

P5875

Q24629580-7DF10D24-4789-4D34-921C-05E151B78B7B

P698

Q24629580-DCF72D1F-39AA-4E3E-AC3A-07B4CC3F9D56

P921

Q24629580-0B8A6B3A-9A61-4542-B575-3F85804240AC

Q24629580-643789D4-DC4E-4E19-BC36-B7207569B03C

Q24629580-D84A8C24-3A97-44AE-ADF5-4C38D5EC5A79

P932

Q24629580-E128E6C2-3D7E-4CF1-9FEB-53A9823E0C61

P356

J.JACC.2008.04.009

P1433

Journal of the American College of Cardiology

P1476

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

@en

P2093

Jacqueline Suk Danik

http://www.w3.org/2001/XMLSchema#string

Paul M Ridker

http://www.w3.org/2001/XMLSchema#string

P2860

Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

P304

124-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2008.04.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Julie E. Buring

P577

2008-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5254280

http://www.w3.org/2001/XMLSchema#string

P698

18598891

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

2958092

http://www.w3.org/2001/XMLSchema#string